新光药业
(300519)
| 流通市值：15.86亿 | | | 总市值：22.24亿 |
| 流通股本：1.14亿 | | | 总股本：1.60亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 88,469,330.56 | 265,359,823.7 | 205,618,567.89 | 140,942,929.2 |
| 营业收入 | 88,469,330.56 | 265,359,823.7 | 205,618,567.89 | 140,942,929.2 |
| 二、营业总成本 | 59,792,683.17 | 208,296,602.07 | 155,285,531.11 | 108,227,514.07 |
| 营业成本 | 48,334,866.13 | 162,503,315.71 | 125,173,396.18 | 89,363,811.65 |
| 税金及附加 | 1,567,560.49 | 5,095,515.06 | 3,605,166.86 | 2,413,791.93 |
| 销售费用 | 4,124,410.42 | 20,098,115.72 | 14,179,746.86 | 10,766,493.8 |
| 管理费用 | 3,915,917.36 | 18,363,756.82 | 13,316,157.76 | 9,356,667.78 |
| 研发费用 | 2,826,423.66 | 13,349,594.41 | 10,041,721.84 | 6,985,742.65 |
| 财务费用 | -976,494.89 | -11,113,695.65 | -11,030,658.39 | -10,658,993.74 |
| 其中:利息收入 | 979,497.89 | 11,125,953.79 | 11,040,362.05 | 10,666,340.74 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | 999,576.46 | 5,630,250.11 | 2,927,590.47 | 2,185,287.2 |
| 资产处置收益 | - | -3,722.27 | -3,722.27 | -3,722.27 |
| 资产减值损失(新) | 103,348.75 | -435,419.57 | -62,904.72 | -177,676.58 |
| 信用减值损失(新) | 163,550.4 | 202,874.74 | -34,170.9 | 47,189.54 |
| 其他收益 | 524,748.49 | 2,407,058 | 1,862,616.76 | 1,305,497.17 |
| 四、营业利润 | 30,467,871.49 | 64,864,262.64 | 55,022,446.12 | 36,071,990.19 |
| 加:营业外收入 | - | 334,427.08 | 295,080.08 | 229,943.2 |
| 减:营业外支出 | - | 1,771,616.74 | 1,745,786.82 | 16,449.8 |
| 五、利润总额 | 30,467,871.49 | 63,427,072.98 | 53,571,739.38 | 36,285,483.59 |
| 减:所得税费用 | 4,099,896.15 | 9,215,614.46 | 8,235,561.04 | 4,377,787.18 |
| 六、净利润 | 26,367,975.34 | 54,211,458.52 | 45,336,178.34 | 31,907,696.41 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 26,367,975.34 | 54,211,458.52 | 45,336,178.34 | 31,907,696.41 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 26,367,975.34 | 54,211,458.52 | 45,336,178.34 | 31,907,696.41 |
| 扣除非经常损益后的净利润 | 25,238,534.55 | 49,592,104.44 | 43,488,621.89 | 29,439,271.34 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.16 | 0.34 | 0.28 | 0.2 |
| (二)稀释每股收益 | 0.16 | 0.34 | 0.28 | 0.2 |
| 八、其他综合收益 | -122,750.41 | 67,953.34 | 80,363.36 | 218,506.15 |
| 归属于母公司股东的其他综合收益 | -122,750.41 | 67,953.34 | 80,363.36 | 218,506.15 |
| 九、综合收益总额 | 26,245,224.93 | 54,279,411.86 | 45,416,541.7 | 32,126,202.56 |
| 归属于母公司股东的综合收益总额 | 26,245,224.93 | 54,279,411.86 | 45,416,541.7 | 32,126,202.56 |
| 公告日期 | 2026-04-21 | 2026-04-21 | 2025-10-28 | 2025-08-26 |
| 审计意见(境内) | | 标准无保留意见 | | |